Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.

Xinle Cui,Zhouhong Cao,Quanyi Chen,Swadhinya Arjunaraja,Andrew L Snow,Clifford M Snapper

Vaccine（2016）

引用 54|浏览13

暂无评分

摘要

•There is currently no prophylactic vaccine for EBV in clinical use.•EBV gp350 does not prevent EBV infection in a phase II clinical trial.•EBV gH/gL and EBV gB critical for EBV entry into B cells and epithelial cells.•Monomeric and trimeric EBV gH/gL and trimeric gB proteins produced in CHO cells.•Vaccination with EBV gH/gL or gB elicits higher neutralization titers than gp350.

查看译文

关键词

Epstein-Barr virus,Vaccine,Antibody,B cell,Recombinant protein,Rabbit,EBV gp350,EBV gH/gL,EBV gB

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要